These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 10187588)

  • 1. Providing health economic data to managed care.
    Navarro RP
    Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588
    [No Abstract]   [Full Text] [Related]  

  • 2. Increasing stakes and complex dynamics in the formulary process.
    Tadlock C
    Manag Care Interface; 2007 Mar; 20(3):12, 14. PubMed ID: 17458473
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA considers effects of managed care marketplace on drug promotional practices.
    Wechsler J
    Formulary; 1995 Dec; 30(12):840-1. PubMed ID: 10153083
    [No Abstract]   [Full Text] [Related]  

  • 4. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 5. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raising the bar in the formulary decision process.
    Navarro RP
    Manag Care Interface; 1999 Jul; 12(7):51, 54. PubMed ID: 10539501
    [No Abstract]   [Full Text] [Related]  

  • 7. The Academy of Managed Care Pharmacy's format for formulary submission.
    Penna P
    Manag Care Interface; 2001 Jun; 14(6):61-2. PubMed ID: 11432152
    [No Abstract]   [Full Text] [Related]  

  • 8. Why doctors should worry about preemption.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology: drug and device export reform.
    Betz R
    J Healthc Resour Manag; 1995 Oct; 13(10):30, 33. PubMed ID: 10151686
    [No Abstract]   [Full Text] [Related]  

  • 11. Controlling the cost of branded drugs.
    Mandelker J
    Bus Health; 1993 Nov; 11(13):44-6, 48. PubMed ID: 10130506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulary submission process catches on ... slowly.
    Cross M
    Manag Care; 2002 Nov; 11(11):32-6. PubMed ID: 12491856
    [No Abstract]   [Full Text] [Related]  

  • 13. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the anticipation of biosimilars: how must a P&T committee gear up?
    Tadlock C
    Manag Care Interface; 2007 Apr; 20(4):12, 14. PubMed ID: 17536251
    [No Abstract]   [Full Text] [Related]  

  • 15. Prescription costs become harder to swallow. Providers and payers get a big dose of reality with explosive spending and patient demand for new drugs.
    Hensley S
    Mod Healthc; 1999 Aug; 29(34):30-4. PubMed ID: 10557476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economics of lipid management.
    Mullins CD
    Manag Care; 2001 Nov; 10(11 Suppl):17-8; discussion 19-24. PubMed ID: 11761626
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of drug industry marketing practices on formularies questioned by federal agencies.
    Gatty B
    Hosp Formul; 1994 Nov; 29(11):786, 785. PubMed ID: 10138576
    [No Abstract]   [Full Text] [Related]  

  • 18. Enterprise liability for bad outcomes from drug therapy: the doctor, the hospital, the pharmacy, and the drug firm.
    Furrow BR
    Spec Law Dig Health Care Law; 1998 Apr; (229):9-69. PubMed ID: 10178162
    [No Abstract]   [Full Text] [Related]  

  • 19. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.
    Bierut MB
    Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552
    [No Abstract]   [Full Text] [Related]  

  • 20. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
    O'Reilly JT
    Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.